With clear PhII win in IBD, Prometheus thwarts Pfiz­er com­par­isons as it fol­lows Hu­mi­ra 'play­book'

Prometheus Bio­sciences re­port­ed a clear Phase II win in two in­flam­ma­to­ry bow­el dis­ease con­di­tions in a clin­i­cal de­vel­op­ment race with Pfiz­er, plant­i­ng the biotech’s flag …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER